Our latest roundup of venture capital financings in the biotech sector includes impressive rounds for SonoThera, Ethyreal, CeQur, and City Therapeutics.

我们最新整理的生物技术领域风险投资融资汇总包括SonoThera、Ethyreal、CeQur和City Therapeutics的令人印象深刻的融资轮次。

SonoThera raises $125m for genetic medicines

SonoThera为基因药物融资1.25亿美元

San Francisco-based SonoThera closed an oversubscribed $125 million Series B financing round, saying it will use the proceeds to advance programmes for Duchenne muscular dystrophy (DMD) and autosomal dominant polycystic kidney disease (ADPKD) into clinical testing, and expand its pipeline of ultrasound-mediated nonviral genetic therapies..

总部位于旧金山的SonoThera公司完成了一轮超额认购的1.25亿美元B轮融资，并表示将利用所得资金推进针对杜氏肌营养不良症（DMD）和常染色体显性多囊肾病（ADPKD）的项目进入临床试验阶段，同时拓展其超声介导的非病毒基因疗法产品管线。

The company's mission is to overcome the limitations of current gene therapies, often related to the safety and effectiveness of delivery vehicles, with the development of targeted, redosable genetic payloads that are delivered using microbubbles – already used for imaging purposes – and released only at specific target cells and tissues selected using localised ultrasound signals..

该公司的使命是通过开发靶向且可重复给药的基因载荷，克服当前基因疗法在递送载体安全性和有效性方面的局限。这些基因载荷借助已用于成像目的的微泡进行递送，并仅在通过局部超声信号选定的特定靶细胞和组织中释放。

The financing was led by Vida Ventures, with participation from ARK Invest, CureDuchenne Ventures, Leaps by Bayer, Otsuka Pharmaceutical, SymBiosis, UCB Ventures SA, Vivo Capital, and existing investors.

本轮融资由Vida Ventures领投，ARK Invest、CureDuchenne Ventures、拜耳旗下Leaps by Bayer、大冢制药、SymBiosis、UCB Ventures SA、Vivo Capital以及现有投资者参投。

Ethyreal Bio emerges with $101m for thyroid disorder drugs

Ethyreal Bio 获得1.01亿美元融资，用于开发甲状腺疾病药物

Massachusetts-based Ethyreal Bio's $101 million in first- and second-round financing will fund the development of an anti-TSHR antibody for thyroid eye disease (TED) and Graves' disease (GD) that is due to start human trials this year.

总部位于马萨诸塞州的Ethyreal Bio公司完成的1.01亿美元首轮融资和第二轮融资，将用于开发一种针对甲状腺眼病（TED）和格雷夫斯病（GD）的抗TSHR抗体，该抗体预计将于今年启动人体临床试验。

If it reaches the market, Ethyrea's ETHY-001 drug would be a rival to Amgen's IGF-1 inhibitor

如果Ethyrea的ETHY-001药物上市，它将成为安进公司IGF-1抑制剂的竞争对手。

Tepezza

替佩扎

(teprotumumab), which was the first drug to be approved by the FDA for TED in 2020, achieving sales of $1.9 billion last year. Both TED and Graves are autoimmune disorders, attacking tissues of the eyes and the thyroid, respectively, and are often seen simultaneously in the same individual. However, current treatments treat each condition separately, and Ethyreal is hoping that targeting TSHR will allow it to deliver a medicine that can treat both at the same time..

(teprotumumab) 是2020年FDA批准的首个用于治疗甲状腺眼病（TED）的药物，去年销售额达19亿美元。TED和格雷夫斯病均为自身免疫性疾病，分别攻击眼部组织和甲状腺组织，且常在同一患者身上同时出现。然而，目前的治疗方法分别针对这两种疾病，而Ethyreal公司希望，通过靶向促甲状腺激素受体（TSHR），能够开发出一种可同时治疗这两种疾病的药物。

The Series A was co-led by Atlas Venture and Medicxi Ventures, alongside Nandi Life Sciences and Checkpoint Capital while the Series B was led by Avoro Capital.

A轮融资由Atlas Venture和Medicxi Ventures联合领投，Nandi Life Sciences和Checkpoint Capital参与投资；B轮融资则由Avoro Capital领投。

CeQur adds $100m to speed its insulin patch rollout

CeQur 追加 1 亿美元以加速其胰岛素贴片的推广

In the medtech arena, Switzerland's CeQur completed a Series E financing, raising $100 million that is earmarked for accelerating the 'commercial growth' of its CeQur Simplicity insulin patch, designed as a discreet alternative to mealtime injections.

在医疗科技领域，瑞士公司CeQur完成了E轮融资，筹集1亿美元，资金将用于加速其CeQur Simplicity胰岛素贴片的“商业增长”，该产品旨在为餐时注射提供一种隐蔽的替代方案。

First approved by the FDA in 2021, the non-digital, mechanical patch is filled with rapid-acting insulin and can be worn for up to seven continuous days before being replaced, filling a gap between insulin pens and automated insulin pumps. Users press two buttons on the side of the device to deliver a dose when needed..

该非数字化机械贴片于2021年首次获得美国食品药品监督管理局（FDA）批准，内含速效胰岛素，可连续佩戴长达七天后再行更换，填补了胰岛素笔与自动胰岛素泵之间的空白。用户在需要时按下设备侧面的两个按钮即可输注一剂胰岛素。

CeQur said the new funding will 'accelerate growth across every dimension of the commercial operation' and will go towards expanding the company's sales teams, as well as its manufacturing capacity and R&D into new products.

CeQur表示，新融资将“加速商业运营各个维度的增长”，资金将用于扩大公司的销售团队，以及提升制造能力和开展新产品的研发。

City Therapeutics targets three clinical-stage assets by year-end

City Therapeutics 计划在年底前推进三项临床阶段资产

Fuelled by its $99.5 million Series B, Massachusetts biotech

在9950万美元B轮融资的推动下，马萨诸塞州的生物技术公司

City Therapeutics

城市疗法公司

– a specialist in RNA interference (RNAi) therapies chaired by former Alnylam CEO John Maraganore – is expecting to add two additional clinical-stage projects to its lead programme for thromboembolic diseases in phase 1.

– 一家由前Alnylam首席执行官John Maraganore担任主席的RNA干扰（RNAi）疗法专业公司 – 预计将在其针对血栓栓塞性疾病的主要项目中增加两个处于临床阶段的项目，进入第一阶段。

Proceeds will be used to fund a recently started study of CITY-FXI, an RNAi against coagulation Factor XI, which has emerged in recent years as a target for novel anticoagulant therapies. It will also support the start of clinical trials of CITY-RBP4 for inherited retinal disorder Stargardt disease, which has shown promise in preclinical testing, along with a third, unidentified project, by the end of 2026..

所得资金将用于资助最近启动的CITY-FXI研究，CITY-FXI是一种针对凝血因子XI的RNAi疗法，而凝血因子XI近年来已成为新型抗凝疗法的靶点。此外，资金还将支持在2026年底前启动CITY-RBP4的临床 trials，该药用于治疗遗传性视网膜疾病斯塔加特病（Stargardt disease），已在临床前测试中展现出潜力；同时还将支持第三个未公开的项目。

The round saw participation from new backers Viking Global Investors and Sofinnova Investments, along with Casdin Capital and NYBC Ventures, and existing investors that include ARCH Venture Partners, Fidelity Management & Research, Invus, Slate Path Capital, Rock Springs Capital, Regeneron Ventures, and AN Ventures..

本轮融资吸引了新投资方 Viking Global Investors 和 Sofinnova Investments，以及 Casdin Capital 和 NYBC Ventures 的参与，现有投资方包括 ARCH Venture Partners、Fidelity Management & Research、Invus、Slate Path Capital、Rock Springs Capital、Regeneron Ventures 和 AN Ventures。

Photo by

照片由

Precondo CA

Precondo 加拿大

on

开

Unsplash

Unsplash